Eli Lilly and Company $LLY Shares Sold by SeaCrest Wealth Management LLC

SeaCrest Wealth Management LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 12.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,108 shares of the company’s stock after selling 1,932 shares during the quarter. Eli Lilly and Company makes up about 1.2% of SeaCrest Wealth Management LLC’s investment portfolio, making the stock its 12th largest position. SeaCrest Wealth Management LLC’s holdings in Eli Lilly and Company were worth $10,997,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of LLY. Duquesne Family Office LLC grew its holdings in shares of Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after acquiring an additional 32,640 shares in the last quarter. Corient IA LLC bought a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $570,000. LS Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock worth $1,933,000 after purchasing an additional 40 shares during the last quarter. Cutter Capital Management LP acquired a new position in Eli Lilly and Company during the first quarter worth about $14,866,000. Finally, Prism Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $207,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Guggenheim decreased their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. UBS Group cut their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, HSBC raised Eli Lilly and Company from a “reduce” rating to a “hold” rating and lifted their target price for the stock from $675.00 to $700.00 in a report on Wednesday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $939.61.

Insider Activity

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $753.52 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $939.86. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $713.18 billion, a P/E ratio of 49.25, a P/E/G ratio of 1.06 and a beta of 0.47. The firm’s 50-day moving average price is $738.37 and its two-hundred day moving average price is $771.89.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were paid a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company’s dividend payout ratio (DPR) is 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.